A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over radiotherapy alone.1 Mechanisms proposed to explain this effect include ...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for ...

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.

Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ...

Astellas Pharma has agreed to co-develop and co-commercialize Vir Biotechnology’s prostate cancer candidate VIR-5500 through a collaboration that could generate more than $1.7 billion for the San ...

When cancer-driving proteins resist various treatments, Northwestern University scientists have uncovered a new solution. Don't fight them - throw them in the cellular trash.

Rahul Parikh, MD, a professor of medicine at the University of Kansas (KU) Medical Center, discussed the critical role of ...

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, ...

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

Researchers are evaluating the P-CARE model, which integrates results from a blended genome-exome sequencing assay and family ...